BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 21, 2013
View Archived Issues
A groundbreaking technique to aid accurate network imaging in intact brains
Read More
Dual mTORC1/2 inhibitor shows promise as immunosuppressant in vivo
Read More
The development of probes to determine the therapeutic potential of epigenetic inhibitors
Read More
Clinical results presented for a novel cancer immunotherapy
Read More
Phase IIa studies indicate GFT-505 may reduce remnant cholesterol
Read More
Helsinn and Vifor sign agreement for netupitant/palonosetron fixed-dose combination
Read More
Bayer seeks approval for riociguat in Japan
Read More
AbbVie and Galapagos add Crohn's disease to GLPG-0634 collaboration
Read More
Novo Nordisk reports results from first phase III trial of N9-GP
Read More
FDA clears Oramed's IND to test ORMD-0801 oral insulin
Read More
Otsuka reports on regulatory and clinical developments of fiscal 2012
Read More
Curie-Cancer and Roche partner further on translational research programs
Read More
Sanofi reports topline data from pivotal phase III JAKARTA study
Read More
XenoPort ends development of arbaclofen placarbil for MS spasticity
Read More
Bydureon launched in Japan
Read More
Breakthrough therapy designation for Synageva's sebelipase alfa
Read More
Astex Therapeutics designs novel FGFR inhibitors
Read More
Scientists at GlaxoSmithKline present new agents for cancer
Read More
FDA grants orphan drug status to ibrutinib, terguride and HIRMAb-IDS
Read More
New mTOR inhibitors disclosed by Novartis
Read More
Novel cannabinoid CB2 receptor agonists synthesized at Roche
Read More
Pfizer ends phase III trial of inotuzumab ozogamicin
Read More
Sanofi divulges novel PKC-beta 2 inhibitors
Read More
FDA advisory committee sets date to review MoxDuo NDA
Read More
Reva Medical offers update on development of ReZolve and ReZolve2 scaffolds
Read More
High efficacy and long duration of a new formulation of NAG-MLP and chol-siRNAs
Read More